208 related articles for article (PubMed ID: 32251122)
1. A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.
McDonald PC; Chia S; Bedard PL; Chu Q; Lyle M; Tang L; Singh M; Zhang Z; Supuran CT; Renouf DJ; Dedhar S
Am J Clin Oncol; 2020 Jul; 43(7):484-490. PubMed ID: 32251122
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
Carta F; Vullo D; Osman SM; AlOthman Z; Supuran CT
Bioorg Med Chem; 2017 May; 25(9):2569-2576. PubMed ID: 28347633
[TBL] [Abstract][Full Text] [Related]
3. SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX.
Eldehna WM; Abo-Ashour MF; Berrino E; Vullo D; Ghabbour HA; Al-Rashood ST; Hassan GS; Alkahtani HM; Almehizia AA; Alharbi A; Abdel-Aziz HA; Supuran CT
Bioorg Chem; 2019 Mar; 83():549-558. PubMed ID: 30471577
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers.
Williams KJ; Gieling RG
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31810330
[TBL] [Abstract][Full Text] [Related]
5. Effect of Carbonic Anhydrase IX inhibitors on human endothelial cell survival.
Genah S; Angeli A; Supuran CT; Morbidelli L
Pharmacol Res; 2020 Sep; 159():104964. PubMed ID: 32485281
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.
Mboge MY; Combs J; Singh S; Andring J; Wolff A; Tu C; Zhang Z; McKenna R; Frost SC
J Med Chem; 2021 Feb; 64(3):1713-1724. PubMed ID: 33523653
[TBL] [Abstract][Full Text] [Related]
7. Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells.
Petrenko M; Güttler A; Funtan A; Keßler J; Emmerich D; Paschke R; Vordermark D; Bache M
Chem Biol Interact; 2021 Jan; 333():109326. PubMed ID: 33245928
[TBL] [Abstract][Full Text] [Related]
8. Perfusion-Based Bioreactor Culture and Isothermal Microcalorimetry for Preclinical Drug Testing with the Carbonic Anhydrase Inhibitor SLC-0111 in Patient-Derived Neuroblastoma.
Huo Z; Bilang R; Supuran CT; von der Weid N; Bruder E; Holland-Cunz S; Martin I; Muraro MG; Gros SJ
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328549
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
Wagner AJ; Messersmith WA; Shaik MN; Li S; Zheng X; McLachlan KR; Cesari R; Courtney R; Levin WJ; El-Khoueiry AB
Clin Cancer Res; 2015 Mar; 21(5):1044-51. PubMed ID: 25388167
[TBL] [Abstract][Full Text] [Related]
10. Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.
Elbadawi MM; Eldehna WM; Nocentini A; Abo-Ashour MF; Elkaeed EB; Abdelgawad MA; Alharbi KS; Abdel-Aziz HA; Supuran CT; Gratteri P; Al-Sanea MM
Eur J Med Chem; 2021 Jun; 218():113360. PubMed ID: 33773285
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
Eldehna WM; Abo-Ashour MF; Nocentini A; El-Haggar RS; Bua S; Bonardi A; Al-Rashood ST; Hassan GS; Gratteri P; Abdel-Aziz HA; Supuran CT
Eur J Med Chem; 2019 Jan; 162():147-160. PubMed ID: 30445264
[TBL] [Abstract][Full Text] [Related]
12. Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors.
Shaldam M; Eldehna WM; Nocentini A; Elsayed ZM; Ibrahim TM; Salem R; El-Domany RA; Capasso C; Abdel-Aziz HA; Supuran CT
Eur J Med Chem; 2021 Apr; 216():113283. PubMed ID: 33667848
[TBL] [Abstract][Full Text] [Related]
13. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
Supuran CT
Expert Opin Investig Drugs; 2018 Dec; 27(12):963-970. PubMed ID: 30426805
[TBL] [Abstract][Full Text] [Related]
15. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: Determination of their carbonic anhydrase inhibitory activity and molecular modeling studies.
Abo-Ashour MF; Eldehna WM; Nocentini A; Ibrahim HS; Bua S; Abdel-Aziz HA; Abou-Seri SM; Supuran CT
Bioorg Chem; 2019 Jun; 87():794-802. PubMed ID: 30978604
[TBL] [Abstract][Full Text] [Related]
16. The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells.
Peppicelli S; Andreucci E; Ruzzolini J; Bianchini F; Nediani C; Supuran CT; Calorini L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1185-1193. PubMed ID: 32396749
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
Bozdag M; Carta F; Ceruso M; Ferraroni M; McDonald PC; Dedhar S; Supuran CT
J Med Chem; 2018 Jul; 61(14):6328-6338. PubMed ID: 29962205
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
